Approval Package for:

APPLICATION NUMBER:

206162Orig1s007

Trade Name: Lynparza

Generic or Proper Name: olaparib

Sponsor: AstraZeneca Pharmaceuticals LP

Approval Date: August 17, 2017

Indication: Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
## CONTENTS

Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Category</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td>X</td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology / Virology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td></td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:

206162Orig1s007

APPROVAL LETTER
Dear Dr. McCullough:

Please refer to your Supplemental New Drug Application (sNDA) dated May 17, 2017, received May 17, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lynparza® (olaparib), oral capsules.

This Prior Approval supplemental new drug application provides for updates to the Prescribing Information based on the post-marketing signal of hypersensitivity characterized by rash and dermatitis. In addition, this supplement provides, via cross-reference to NDA 208558 for Lynparza® (olaparib) tablets, the final clinical study report for PMR 2824-1 from the December 19, 2014, approval letter for this NDA. Notifications were added to the Prescribing Information regarding the differences in the dosing and bioavailability of the capsule and tablet formulations.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

The SPL will be accessible from publicly available labeling repositories. Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**SUBPART H FULFILLED**

We approved this NDA under the regulations at 21 CFR 314 Subpart H for accelerated approval of new drugs for serious or life-threatening illnesses. Approval of this supplement fulfills your commitment made under 21 CFR 314.510 for the following postmarketing requirement:

**2824-1**

Submit the progression-free survival (PFS) and overall survival (OS) analyses with datasets from clinical trial D0818C00002, SOLO-2, the ongoing randomized double-blind, placebo-controlled, multi-center trial to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum-based chemotherapy.

- Interim Report (PFS analysis) 02/2016
- Trial Completion Date 12/2018
- Final Report Submission (OS analysis) 03/2019

**RELEASE FROM POSTMARKETING REQUIREMENT**

We have received your submission dated August 14, 2017, providing authorization to cross-reference NDA 208558 for the final clinical study report for PMR 2824-1 listed in our December 19, 2014, approval letter:

**2824-2**

Submit the progression-free survival (PFS) and overall survival (OS) analyses with datasets from clinical trial D0816C00010, a randomized trial establishing the superiority of olaparib over physician’s choice single-agent chemotherapy in the treatment of platinum sensitive relapsed ovarian cancer in patients carrying deleterious or suspected deleterious germline BRCA1/2 mutations.
The original timetable you submitted on November 13, 2014, states that you will conduct this trial according to the following schedule:

- Interim report: 06/2018
- Trial Completion Date: 03/2020
- Final Report Submission: 06/2020

We have reviewed your submission and have determined that you are released from the above postmarketing requirement for the following reasons:

Interim progression-free survival data from SOLO-2 have verified the clinical benefit of olaparib and therefore olaparib capsules for monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy is granted regular approval. Therefore, PMR 2824-2 is no longer needed.

We remind you that there are postmarketing requirements listed in the December 19, 2014, approval letter that are still open.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:
You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf). Information and Instructions for completing the form can be found at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf). For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rajesh Venugopal, Senior Regulatory Project Manager, at (301) 796-4730.

Sincerely,

*See appended electronic signature page*

Julia Beaver, MD
Acting Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

------------------------------------------
JULIA A BEAVER
08/17/2017

Reference ID: 4140741
LYNPARZA® (olaparib) capsules, for oral use

Initial U.S. Approval: 2014

RECENT MAJOR CHANGES

Indications and Usage (1.1) 08/2017
Dosage and Administration (2.2) 01/2017
Dosage and Administration (2.5) 10/2016
Warnings and Precautions (5.1) 10/2016
Warnings and Precautions (5.3) 01/2017

INDICATIONS AND USAGE

Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. (1.1)

DOSE AND ADMINISTRATION

To avoid substitution errors and overdose, do not substitute Lynparza capsules with Lynparza tablets on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation. (2.2)

Recommended dose is 400 mg taken orally twice daily with or without food. (2.3)

Continue treatment until disease progression or unacceptable toxicity. (2.3)

For adverse reactions, consider dose interruption of treatment or dose reduction. (2.4)

For moderate renal impairment (CLcr 31-50 mL/min), reduce dose to 300 mg twice daily. (2.6)

Dosage Forms and Strengths

Capsules: 50 mg. (3)

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): occurred in patients exposed to Lynparza, and the majority of reports were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed. (5.1)

Pneumonitis: occurred in patients exposed to Lynparza, and some cases were fatal. Interrupt treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed. (5.2)

Embryo-Fetal Toxicity: Lynparza can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.3, 8.1, 8.3)

ADVERSE REACTIONS

Most common adverse reactions (≥20%) in clinical trials were anemia, nausea, fatigue (including asthenia), vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis/pharyngitis/URI, cough, arthralgia/musculoskeletal pain, myalgia, back pain, dermatitis/rash and abdominal pain/discomfort. (6.1)

Most common laboratory abnormalities (≥25%) were increase in creatinine, mean corpuscular volume elevation, decrease in hemoglobin, decrease in lymphocytes, decrease in absolute neutrophil count, and decrease in platelets. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

CYP3A Inhibitors: Avoid concomitant use of strong and moderate CYP3A inhibitors. If the inhibitor cannot be avoided, reduce the dose. (7.2)

CYP3A Inducers: Avoid concomitant use of strong and moderate CYP3A inducers. If a moderate CYP3A inducer cannot be avoided, be aware of a potential for decreased efficacy. (7.3)

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and MEDICATION GUIDE.

Revised: 8/2017

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
1.1 Treatment of gBRCA-mutated Advanced Ovarian Cancer

2 DOSAGE AND ADMINISTRATION
2.1 Patient Selection
2.2 Important Administration Instructions
2.3 Recommended Dosing
2.4 Dose Adjustments for Adverse Reactions
2.5 Dose Modifications for Use with CYP3A Inhibitors
2.6 Dose Modifications for Patients with Renal Impairment

3 DOSAGE FORMS AND STRENGTHS

Capsules: 50 mg. (3)

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS
5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia
5.2 Pneumonitis
5.3 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS
6.1 Clinical Trial Experience
6.2 Postmarketing Experience

7 DRUG INTERACTIONS
7.1 Anticancer Agents
7.2 Drugs That May Increase Olaparib Plasma Concentrations
7.3 Drugs That May Decrease Olaparib Plasma Concentrations

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.3 Females and Males of Reproductive Potential
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Hepatic Impairment
8.7 Renal Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
16.2 Storage

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Treatment of gBRCA-mutated Advanced Ovarian Cancer
Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection
Select patients for the treatment of advanced ovarian cancer with Lynparza based on the presence of deleterious or suspected deleterious germline BRCA-mutations [see Indications and Usage (1) and Clinical Studies (14)]. Information on FDA-approved test for the detection of BRCA-mutations is available at http://www.fda.gov/companiondiagnostics.

2.2 Important Administration Instructions
Lynparza is also available as 100 mg and 150 mg tablets. DO NOT substitute Lynparza capsules (50 mg) with Lynparza tablets (100 mg and 150 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation. Refer to the full prescribing information for Lynparza tablets for specific tablet dosing.

2.3 Recommended Dosing
The recommended dose of Lynparza is 400 mg (eight 50 mg capsules) taken orally twice daily with or without food, for a total daily dose of 800 mg.

Continue treatment until disease progression or unacceptable toxicity.

If a patient misses a dose of Lynparza, instruct patients to take their next dose at its scheduled time.

Swallow capsule whole. Do not chew, dissolve, or open capsule. Do not take capsules which appear deformed or show evidence of leakage [see How Supplied/Storage and Handling (16.2)].

2.4 Dose Adjustments for Adverse Reactions
To manage adverse reactions, consider dose interruption of treatment or dose reduction.

The recommended dose reduction is to 200 mg (four 50 mg capsules) taken twice daily, for a total daily dose of 400 mg.

If a further final dose reduction is required, then reduce to 100 mg (two 50 mg capsules) taken twice daily, for a total daily dose of 200 mg.

Reference ID: 4140741
2.5 Dose Modifications for Use with CYP3A Inhibitors
Avoid concomitant use of strong and moderate CYP3A inhibitors and consider alternative agents with less CYP3A inhibition. If the inhibitor cannot be avoided, reduce the Lynparza dose to 150 mg (three 50 mg capsules) taken twice daily for a strong CYP3A inhibitor or 200 mg (four 50 mg capsules) taken twice daily for a moderate CYP3A inhibitor [see Drug Interactions (7.2)].

2.6 Dose Modifications for Patients with Renal Impairment
Patients with mild renal impairment (CLcr 51-80 mL/min as estimated by Cockcroft-Gault) do not require an adjustment in Lynparza dosing. In patients with moderate renal impairment (CLcr 31-50 mL/min) the recommended dose reduction is to 300 mg (six 50 mg capsules) taken twice daily, for a total daily dose of 600 mg. The pharmacokinetics of olaparib have not been evaluated in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS
Capsules (50 mg): white, opaque, marked in black ink with “OLAPARIB 50 mg” on the cap and the AstraZeneca logo on the body.

4 CONTRAINDICATIONS
None.

5 WARNINGS AND PRECAUTIONS

5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) have been confirmed in 6 out of 298 (2%) patients enrolled in a single arm trial of Lynparza monotherapy, in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced cancers. In a randomized placebo controlled trial, MDS/AML occurred in 3 out of 136 (2%) patients with advanced ovarian cancer treated with Lynparza. Overall, MDS/AML were reported in <1% patients treated with Lynparza in clinical studies. The majority of MDS/AML reports were fatal, and the duration of therapy with Lynparza in patients who developed secondary MDS/cancer-therapy related AML varied from <6 months to >2 years. All of these patients had previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy. Some of these patients also had a history of previous cancer or of bone marrow dysplasia.

Monitor complete blood count testing at baseline and monthly thereafter. Do not start Lynparza until patients have recovered from hematological toxicity caused by previous chemotherapy (≤Grade 1). For prolonged hematological toxicities, interrupt Lynparza and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Lynparza.
5.2 Pneumonitis
Pneumonitis, including fatal cases, occurred in <1% of patients treated with Lynparza. If patients present with new or worsening respiratory symptoms such as dyspnea, fever, cough, wheezing, or a radiological abnormality occurs, interrupt treatment with Lynparza and initiate prompt investigation. If pneumonitis is confirmed, discontinue Lynparza.

5.3 Embryo-Fetal Toxicity
Lynparza can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. In an animal reproduction study, administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 400 mg twice daily. Apprise pregnant women of the potential hazard to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Lynparza [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].

6 ADVERSE REACTIONS
The following adverse reactions are discussed elsewhere in the labeling:

- Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions (5.1)]
- Pneumonitis [see Warnings and Precautions (5.2)]

6.1 Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Lynparza 400 mg twice daily as monotherapy, has been studied in 300 patients with gBRCA-mutated advanced ovarian cancer, and 223 of these patients had received 3 or more prior lines of chemotherapy.

In the 223 patients with gBRCA-mutated ovarian cancer who received 3 or more prior lines of chemotherapy (including 137 patients in Study 1 with measureable disease) [see Clinical Studies (14)] adverse reactions led to dose interruption in 40% of patients, dose reduction in 4%, and discontinuation in 7%. There were 8 (4%) patients with adverse reactions leading to death, two were attributed to acute leukemia, and one each was attributed to COPD, cerebrovascular accident, intestinal perforation, pulmonary embolism, sepsis, and suture rupture. The median exposure to Lynparza in these patients was 158 days.

Table 1 and Table 2 summarize the common adverse reactions and abnormal laboratory findings, respectively, observed in patients treated with Lynparza.
Table 1 Adverse Reactions Reported in ≥20% of Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>3 or more lines of prior chemotherapy</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grades 1-4</td>
<td>Grades 3-4</td>
</tr>
<tr>
<td></td>
<td>N=223</td>
<td>N=223</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Blood and Lymphatic disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>34</td>
<td>18</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain/discomfort</td>
<td>43</td>
<td>8</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>22</td>
<td>1</td>
</tr>
<tr>
<td>Nausea</td>
<td>64</td>
<td>3</td>
</tr>
<tr>
<td>Vomiting</td>
<td>43</td>
<td>4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>31</td>
<td>1</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>General disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue/asthenia</td>
<td>66</td>
<td>8</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis/URI</td>
<td>26</td>
<td>0</td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia/musculoskeletal pain</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>Myalgia</td>
<td>22</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 2 Laboratory Abnormalities Reported in ≥25% Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza

<table>
<thead>
<tr>
<th>Laboratory Parameter*</th>
<th>3 or more lines of prior chemotherapy</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grades 1-4</td>
<td>Grades 3-4</td>
</tr>
<tr>
<td></td>
<td>N=223</td>
<td>N=223</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Decrease in hemoglobin</td>
<td>90</td>
<td>15</td>
</tr>
<tr>
<td>Decrease in absolute neutrophil count</td>
<td>25</td>
<td>7</td>
</tr>
<tr>
<td>Decrease in platelets</td>
<td>30</td>
<td>3</td>
</tr>
<tr>
<td>Decrease in lymphocytes</td>
<td>56</td>
<td>17</td>
</tr>
<tr>
<td>Mean corpuscular volume elevation</td>
<td>57</td>
<td>-</td>
</tr>
<tr>
<td>Increase in creatinine*</td>
<td>30</td>
<td>2</td>
</tr>
</tbody>
</table>

* Patients were allowed to enter clinical studies with laboratory values of Grade 1.

The following adverse reactions and laboratory abnormalities have been identified in ≥10 to <20% of the 223 patients receiving Lynparza and not included in the table: cough, constipation, dysgeusia, peripheral edema, back pain, dizziness, headache, urinary tract infection, dyspnea, and rash.

The following adverse reactions and laboratory abnormalities have been identified in ≥1 to <10% of the 223 patients receiving Lynparza and not included in the table: leukopenia, stomatitis, peripheral neuropathy, pyrexia, hypomagnesemia, hyperglycemia, anxiety, depression, insomnia, dysuria, urinary incontinence, vulvovaginal disorder, dry skin/eczema, pruritus, hypertension, venous thrombosis (including pulmonary embolism), and hot flush.

Reference ID: 4140741
Table 3 presents adverse reactions reported in ≥20% of patients from a randomized trial of Lynparza 400 mg twice daily as maintenance monotherapy compared to placebo in patients with platinum sensitive, relapsed, high-grade serous ovarian cancer following treatment with 2 or more platinum-containing regimens. Table 4 presents the laboratory abnormalities in patients from this randomized trial. Of the 96 patients with gBRCA-mutation, 53 received Lynparza, and 43 received placebo. The median duration on treatment with Lynparza was 11.1 months for patients with a gBRCA-mutation compared to 4.4 months for patients with gBRCA-mutation on placebo.

Adverse reactions led to dose interruptions in 26% of those receiving Lynparza and 7% of those receiving placebo; dose reductions in 15% of Lynparza and 5% of placebo patients; and discontinuation in 9% of Lynparza and 0% in placebo patients. One (2%) patient on Lynparza died as a result of an adverse reaction.

Table 3 Adverse Reactions Reported in ≥20% of Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Lynparza N=53</th>
<th>Placebo N=43</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grades 1-4 %</td>
<td>Grades 3-4 %</td>
</tr>
<tr>
<td>Blood and Lymphatic disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>25</td>
<td>4</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain/discomfort</td>
<td>47</td>
<td>0</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>75</td>
<td>2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>32</td>
<td>4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>28</td>
<td>4</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>General disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue (including asthenia, lethargy)</td>
<td>68</td>
<td>6</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis/Pharyngitis/URI</td>
<td>43</td>
<td>0</td>
</tr>
<tr>
<td>Musculoskeletal and Connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia/Musculoskeletal pain</td>
<td>32</td>
<td>4</td>
</tr>
<tr>
<td>Myalgia</td>
<td>25</td>
<td>2</td>
</tr>
<tr>
<td>Back pain</td>
<td>25</td>
<td>6</td>
</tr>
<tr>
<td>Nervous system disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory, Thoracic, Mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>Skin and Subcutaneous Tissue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatitis/Rash</td>
<td>25</td>
<td>0</td>
</tr>
</tbody>
</table>
Table 4 Laboratory Abnormalities in ≥25% Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial

<table>
<thead>
<tr>
<th>Laboratory parameter*</th>
<th>Lynparza N=53</th>
<th>Placebo N=43</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grades 1-4 %</td>
<td>Grades 3-4 %</td>
</tr>
<tr>
<td>Decrease in hemoglobin</td>
<td>85</td>
<td>8</td>
</tr>
<tr>
<td>Decrease in absolute neutrophil count</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>Decrease in platelets</td>
<td>26</td>
<td>6</td>
</tr>
<tr>
<td>Mean corpuscular volume elevation</td>
<td>85</td>
<td>-</td>
</tr>
<tr>
<td>Increase in creatinine*</td>
<td>26</td>
<td>0</td>
</tr>
</tbody>
</table>

* Patients were allowed to enter clinical studies with laboratory values of Grade 1.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Lynparza. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Immune System Disorders**: Hypersensitivity (rash/dermatitis)

7 DRUG INTERACTIONS

7.1 Anticancer Agents

Clinical studies of Lynparza in combination with other myelosuppressive anticancer agents, including DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.

7.2 Drugs That May Increase Olaparib Plasma Concentrations

Olaparib is primarily metabolized by CYP3A. In patients (N=57), co-administration of itraconazole, a strong CYP3A inhibitor, increased AUC of olaparib by 2.7-fold. A moderate CYP3A inhibitor, fluconazole, is predicted to increase the AUC of olaparib by 2.2-fold.

Avoid concomitant use of strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, ketoconazole, voriconazole, nefazodone, posaconazole, ritonavir, lopinavir/ritonavir, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) and moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil). If the strong or moderate CYP3A inhibitors must be co-administered, reduce the dose of Lynparza [see Dosage and Administration (2.4)].

Avoid grapefruit and Seville oranges during Lynparza treatment [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].
7.3 Drugs That May Decrease Olaparib Plasma Concentrations

In patients (N=22), co-administration of rifampicin, a strong CYP3A inducer, decreased AUC of olaparib by 87%. A moderate CYP3A inducer, efavirenz, is predicted to decrease the AUC of olaparib by approximately 50%.

Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampicin, carbamazepine, St. John’s Wort) and moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, nafcillin). If a moderate CYP3A inducer cannot be avoided, be aware of a potential for decreased efficacy of Lynparza [see Clinical Pharmacology (12.3)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1)], Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 400 mg twice daily [see Data]. Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies.

Data

Animal Data

In a fertility and early embryonic development study in female rats, olaparib was administered orally for 14 days before mating through to day 6 of pregnancy, which resulted in increased post-implantation loss at a dose level of 15 mg/kg/day (with maternal systemic exposures approximately 11% of the human exposure (AUC0-24h) at the recommended dose).

In an embryo-fetal development study, pregnant rats received oral doses of 0.05 and 0.5 mg/kg/day olaparib during the period of organogenesis. A dose of 0.5 mg/kg/day (with maternal systemic exposures approximately 0.3% of human exposure (AUC0-24h) at the recommended dose) caused embryo-fetal toxicities including increased post-implantation loss and major malformations of the eyes (anophthalmia, microphthalmia), vertebrae/ribs (extra rib or ossification center; fused or absent neural arches, ribs, and sternebrae), skull (fused exoccipital) and diaphragm (hernia). Additional abnormalities or variants included incomplete or absent ossification (vertebrae/sternebrae, ribs, limbs) and other findings in the vertebrae/sternebrae, pelvic girdle, lung, thymus, liver, ureter and umbilical artery. Some findings noted above in the eyes, ribs and ureter were observed at a dose of 0.05 mg/kg/day olaparib at lower incidence.
8.2 Lactation

Risk Summary

No data are available regarding the presence of olaparib in human milk, or on its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infants from Lynparza, advise a lactating woman not to breastfeed during treatment with Lynparza and for one month after receiving the last dose.

8.3 Females and Males of Reproductive Potential

Pregnancy Testing

Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with Lynparza.

Contraception

Females

Lynparza can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use highly effective contraception during treatment with Lynparza and for at least 6 months following the last dose.

8.4 Pediatric Use

The safety and efficacy of Lynparza have not been established in pediatric patients.

8.5 Geriatric Use

In clinical studies of Lynparza enrolling 735 patients with advanced solid tumors [the majority (69%) of whom had ovarian cancer] who received Lynparza 400 mg twice daily as monotherapy, 148 (20%) of patients were aged ≥65 years. The safety profile was similar irrespective of age with the exception of AEs of CTCAE ≥3 which were reported more frequently in patients aged ≥65 years (53.4%) than those <65 years (43.4%). No individual adverse event or System Organ Class accounted for this observed difference.

8.6 Hepatic Impairment

No adjustment to the starting dose is required in patients with mild hepatic impairment. A 1.2-fold increase in mean exposure (AUC) was observed in patients with mild hepatic impairment (based on Child-Pugh classification A) compared to patients with normal hepatic function. There are no data in patients with moderate or severe hepatic impairment [see Clinical Pharmacology (12.3)].

8.7 Renal Impairment

A 1.2-fold increase in mean exposure (AUC) was observed in patients with mild renal impairment (CLcr = 51-80 mL/min) compared to patients with normal renal function (CLcr >80 mL/min). No dose adjustment to the starting dose is required in patients with mild renal impairment, but patients should be monitored closely for toxicity. A 1.4-fold increase in AUC was observed in patients with moderate renal
impairment (CLcr = 31-50 mL/min) compared to patients with normal renal function (CLcr >80 mL/min). For patients with moderate renal impairment, reduce the dose of Lynparza to 300 mg twice daily [see Dosage and Administration (2.5)]. There are no data in patients with severe renal impairment or end-stage disease (CLcr ≤30 mL/min) [see Clinical Pharmacology (12.3)].

10 OVERDOSAGE

There is no specific treatment in the event of Lynparza overdose, and symptoms of overdose are not established. In the event of an overdose, physicians should follow general supportive measures and should treat symptomatically.

11 DESCRIPTION

Olaparib is an inhibitor of the mammalian polyadenosine 5’-diphosphoriboos polymerase (PARP) enzyme.

The chemical name is 4-[(3-[[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl]-4-fluorophenyl)methyl]phthalazin-1(2H)-one and it has the following chemical structure:

![Chemical Structure of Olaparib]

The empirical molecular formula for Lynparza is C_{24}H_{23}FN_{4}O_{3} and the relative molecular mass is 434.46.

Olaparib is a crystalline solid, is non-chiral and shows pH-independent low solubility of approximately 0.1 mg/mL across the physiological pH range.

Lynparza is available in 50 mg capsules for oral administration. Each capsule contains olaparib as the active ingredient and the following inactive ingredients:

- **Capsule content:** lauroyl polyoxylglycerides
- **Capsule shell:** hypromellose, titanium dioxide, gellan gum, potassium acetate
- **Capsule printing ink:** shellac, ferrosferric oxide
12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

12.3 Pharmacokinetics

Absorption

Following oral administration of olaparib via the capsule formulation, absorption is rapid with peak plasma concentrations typically achieved between 1 to 3 hours after dosing. On multiple dosing there is no marked accumulation (accumulation ratio of 1.4 – 1.5 for twice daily dosing), with steady state exposures achieved within 3 to 4 days.

Limited data suggest that the systemic exposure (AUC) of olaparib increases less than proportionally with dose over the dose range of 100 to 400 mg, but the PK data were variable across trials.

Co-administration with a high fat meal slowed the rate (T<sub>max</sub> delayed by 2 hours) of absorption, but did not significantly alter the extent of olaparib absorption (mean AUC increased by approximately 20%).

Distribution

Olaparib had a mean (± standard deviation) apparent volume of distribution at steady state of 167 ± 196 L after a single 400 mg dose of olaparib. The in vitro protein binding of olaparib at plasma concentrations achieved following dosing at 400 mg twice daily is approximately 82%.

Metabolism

In vitro, CYP3A4 was shown to be the enzyme primarily responsible for the metabolism of olaparib.

Following oral dosing of <sup>14</sup>C-olaparib to female patients, unchanged olaparib accounted for the majority of the circulating radioactivity in plasma (70%). It was extensively metabolized with unchanged drug accounting for 15% and 6% of radioactivity in urine and feces, respectively. The majority of the metabolism is attributable to oxidation reactions with a number of the components produced undergoing subsequent glucuronide or sulfate conjugation.

Excretion

A mean (± standard deviation) terminal plasma half-life of 11.9 ± 4.8 hours and apparent plasma clearance of 8.6 ± 7.1 L/h were observed after a single 400 mg dose of olaparib.
Following a single dose of $^{14}$C-olaparib, 86% of the dosed radioactivity was recovered within a 7-day collection period, 44% via the urine and 42% via the feces. The majority of the material was excreted as metabolites.

**Drug Interactions**

Based on the data from a drug-interaction trial (N=57), the AUC and $C_{\text{max}}$ of olaparib increased by 2.7- and 1.4-fold, respectively, when olaparib was administered in combination with itraconazole, a strong CYP3A inhibitor. Simulations suggested that a moderate CYP3A inhibitor (fluconazole) may increase the AUC and $C_{\text{max}}$ of olaparib by 2.2- and 1.2-fold, respectively.

Based on the data from a drug-interaction trial (N=22), the AUC and $C_{\text{max}}$ of olaparib decreased by 87% and 71%, respectively, when olaparib was administered in combination with rifampicin, a strong CYP3A inducer. Simulations suggested that a moderate CYP3A inducer (efavirenz) may decrease the AUC and $C_{\text{max}}$ of olaparib by approximately 50% and 30%, respectively.

*In vitro* studies have shown that olaparib is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6. Simulations suggested that olaparib may not affect the exposure of a CYP3A substrate in humans. It cannot be excluded that olaparib may induce CYP2C9 and CYP2C19. *In vitro* studies also indicated that olaparib is a substrate of P-gp and an inhibitor of P-gp (MDR1), BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K. The clinical relevance of these findings is unknown. The potential for olaparib to induce P-gp has not been evaluated.

**Pharmacokinetics in Specific Populations**

*Hepatic Impairment*

In a hepatic impairment trial, the mean AUC increased by 15% and the mean $C_{\text{max}}$ by 13% when olaparib was dosed in patients with mild hepatic impairment (Child-Pugh classification A; N=9) compared with patients with normal hepatic function (N=13). Mild hepatic impairment had no effect on the protein binding of olaparib and therefore total plasma exposure was representative of free drug. There are no data in patients with moderate or severe hepatic impairment.

*Renal Impairment*

In a dedicated renal impairment trial, the mean AUC and $C_{\text{max}}$ of olaparib both increased by 1.2-fold, when olaparib was dosed in patients with mild renal impairment ($\text{CL}_{\text{cr}} = 51-80 \text{ mL/min}$ defined by the Cockcroft-Gault equation; N=13) and by 1.4- and 1.3-fold, respectively, when olaparib was dosed in patients with moderate renal impairment ($\text{CL}_{\text{cr}} = 31-50 \text{ mL/min}$; N=13), compared to those with normal renal function ($\text{CL}_{\text{cr}} \geq 81 \text{ mL/min}$; N=12). There was no evidence of a relationship between the extent of plasma protein binding of olaparib and creatinine clearance. There are no data in patients with severe renal impairment or end-stage renal disease ($\text{CL}_{\text{cr}} \leq 30 \text{ mL/min}$).

**13 NONCLINICAL TOXICOLOGY**

**13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Carcinogenicity studies have not been conducted with olaparib.
Olaparib was clastogenic in an *in vitro* chromosomal aberration assay in mammalian CHO cells and in an *in vivo* rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of olaparib and indicates potential for genotoxicity in humans. Olaparib was not mutagenic in a bacterial reverse mutation (Ames) test.

In a fertility study, female rats received oral olaparib at doses of 0.05, 0.5, and 15 mg/kg/day for at least 14 days before mating through the first week of pregnancy. There were no adverse effects on mating and fertility rates at doses up to 15 mg/kg/day (maternal systemic exposures approximately 11% of the human exposure (AUC₀-₂₄h) at the recommended dose).

In a male fertility study, olaparib had no effect on mating and fertility in rats at oral doses up to 40 mg/kg/day following at least 70 days of olaparib treatment (with systemic exposures of approximately 7% of the human exposure (AUC₀-₂₄h) at the recommended dose).

**14 CLINICAL STUDIES**

The efficacy of Lynparza was investigated in a single-arm study in patients with deleterious or suspected deleterious germline *BRCA*-mutated (g*BRCA*m) advanced cancers (Study 1). A total of 137 patients with measurable, g*BRCA*m-associated ovarian cancer treated with three or more prior lines of chemotherapy were enrolled. All patients received Lynparza at a dose of 400 mg twice daily as monotherapy until disease progression or intolerable toxicity. Objective response rate (ORR) and duration of response (DOR) were assessed by the investigator according to RECIST v1.1.

The median age of the patients was 58 years, the majority were Caucasian (94%) and 93% had an ECOG PS of 0 or 1. Deleterious or suspected deleterious, germline *BRCA*-mutation status was verified retrospectively in 97% (59/61) of the patients for whom blood samples were available by the companion diagnostic BRACAnalysis CDx™, which is FDA approved for selection of patients for Lynparza treatment.

Efficacy results from Study 1 are summarized in Table 5.

**Table 5 Overall Response and Duration of Response in Patients with gBRCA-mutated Advanced Ovarian Cancer Who Received 3 or More Prior Lines of Chemotherapy in Study 1**

<table>
<thead>
<tr>
<th></th>
<th>N=137</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective Response Rate (95% CI)</td>
<td>34% (26, 42)</td>
</tr>
<tr>
<td>Complete Response</td>
<td>2%</td>
</tr>
<tr>
<td>Partial Response</td>
<td>32%</td>
</tr>
<tr>
<td>Median DOR in months (95% CI)</td>
<td>7.9 (5.6, 9.6)</td>
</tr>
</tbody>
</table>
16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied
Lynparza 50 mg is a white, opaque, hard capsule, marked in black ink with: “OLAPARIB 50 mg” on the cap and AstraZeneca logo on the body; available in:

Bottles of 112 capsules NDC 0310-0657-58

16.2 Storage
Store at 25ºC (77ºF), excursions permitted to 15ºC -30ºC (59ºF -86ºF) [see USP Controlled Room Temperature]

Lynparza should not be exposed to temperatures greater than 40ºC or 104ºF. Do not take Lynparza if it is suspected of having been exposed to temperatures greater than 40ºC or 104ºF.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

- **Dosing Instructions:** Inform patients on how to take Lynparza [see Dosage and Administration (2.2)]. Lynparza should be taken twice daily with or without food. Instruct patients that if they miss a dose of Lynparza, not to take an extra dose to make up for the one that they missed. They should take their next normal dose at the usual time. Each capsule should be swallowed whole. Do not chew, dissolve, or open the capsule. Patient should not take Lynparza with grapefruit or Seville oranges.

- **Inform patients not** to substitute Lynparza capsules (50 mg) with Lynparza tablets (100 mg and 150 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation [see Dosage and Administration (2.2)].

- **MDS/AML:** Advise patients to contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions. This may be a sign of hematological toxicity or a more serious uncommon bone marrow problem called ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukemia’ (AML) which have been reported in patients treated with Lynparza [see Warnings and Precautions (5.1)].

- **Pneumonitis:** Advise patients to contact their healthcare provider if they experience any new or worsening respiratory symptoms including shortness of breath, fever, cough, or wheezing [see Warnings and Precautions (5.2)].

- **Embryo-Fetal Toxicity:** Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with Lynparza and for 6 months after receiving the last dose [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1, 8.3)].

- **Lactation:** Advise patients not to breastfeed while taking Lynparza and for one month after receiving the last dose [see Use in Special Populations (8.2)].
• **Nausea/vomiting:** Advise patients that mild or moderate nausea and/or vomiting is very common in patients receiving Lynparza and that they should contact their healthcare provider who will advise on available antiemetic treatment options.
**What is the most important information I should know about Lynparza?**

Lynparza may cause serious side effects that can lead to death, including:

**Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).** Some people who have ovarian cancer or who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with Lynparza. If you develop MDS or AML, your healthcare provider will stop treatment with Lynparza.

Symptoms of low blood cell counts are common during treatment with Lynparza, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include:

- weakness
- weight loss
- fever
- frequent infections
- blood in urine or stool
- shortness of breath
- feeling very tired
- bruising or bleeding more easily

Your healthcare provider will do blood tests to check your blood cell counts:

- before treatment with Lynparza
- every month during treatment with Lynparza
- weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with Lynparza until your blood cell counts improve.

**Lung problems (pneumonitis).** Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily stop treatment or completely stop treatment if you develop pneumonitis.

Tell your healthcare provider if you have any of the symptoms above during treatment with Lynparza.

---

**What is Lynparza?**

Lynparza is a prescription medicine used to treat women with advanced ovarian cancer who:

- have received previous treatment with 3 or more prior chemotherapy medicines or a combination of chemotherapy medicines for their cancer, and
- have a certain type of abnormal inherited BRCA gene.

Your healthcare provider will perform a test to make sure that Lynparza is right for you.

It is not known if Lynparza is safe and effective in children.
What should I tell my healthcare provider before taking Lynparza?

Before you take Lynparza, tell your healthcare provider about all of your medical conditions including if you:

- have lung or breathing problems
- have liver problems
- have kidney problems
- are pregnant or plan to become pregnant. Lynparza can harm your unborn baby and may cause loss of pregnancy (miscarriage).
  - If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Lynparza.
  - Females who are able to become pregnant should use effective birth control (contraception) during treatment with Lynparza and for 6 months after receiving the last dose of Lynparza.
  - Talk to your healthcare provider about birth control methods that may be right for you.
  - Tell your healthcare provider right away if you become pregnant.
- are breastfeeding or plan to breastfeed. It is not known if Lynparza passes into your breast milk. Do not breastfeed during treatment with Lynparza and for 1 month after receiving the last dose of Lynparza. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Lynparza and certain other medicines may affect how Lynparza works and may cause side effects.

How should I take Lynparza?

- Take Lynparza exactly as your healthcare provider tells you.
- Your healthcare provider may temporarily stop treatment with Lynparza or change your dose of Lynparza if you have side effects.
- Lynparza comes as capsules and tablets. Lynparza capsules and tablets are not the same. If your healthcare provider prescribes Lynparza capsules for you do not take Lynparza tablets. If you have any questions about Lynparza, talk with your healthcare provider or pharmacist.
- Take Lynparza by mouth 2 times a day. Each dose should be taken 12 hours apart.
- Take Lynparza with or without food.
- Swallow Lynparza capsules whole. Do not chew, dissolve, or open the capsules.
- Do not take Lynparza capsules if they look damaged or show signs of leakage.
- If you miss a dose of Lynparza, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose.
- If you take too much Lynparza, call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking Lynparza?

- Avoid grapefruit, grapefruit juice and Seville oranges during treatment with Lynparza. Grapefruit and Seville oranges may increase the level of Lynparza in your blood.
What are the possible side effects of Lynparza?

Lynparza may cause serious side effects.
See “What is the most important information I should know about Lynparza?”

The most common side effects of Lynparza are:

- nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms.
- tiredness or weakness
- diarrhea
- indigestion or heartburn
- headache
- loss of appetite
- changes in the way food tastes
- changes in kidney function blood test
- sore throat or runny nose
- upper respiratory infection
- cough
- pain in the joints, muscles, and back
- rash
- pain or discomfort in the stomach area

These are not all the possible side effects of Lynparza. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Lynparza?

- Store Lynparza at room temperature, between 68°F to 77°F (20°C to 25°C).
- Do not store Lynparza at temperatures greater than 104°F (40°C). Do not take Lynparza if you think it may have been stored at a temperature greater than 104°F (40°C).

Keep Lynparza and all medicines out of the reach of children.

General information about the safe and effective use of Lynparza

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Lynparza for a condition for which it was not prescribed. Do not give Lynparza to other people, even if they have the same symptoms you have. It may harm them.

If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Lynparza that is written for health professionals.

What are the ingredients in Lynparza?

Active ingredient: olaparib

Inactive ingredients:
Capsule contains: lauroyl polyoxyglycerides
Capsule shell contains: hypromellose, titanium dioxide, gelatin gum, potassium acetate
Capsule printing ink contains: shellac, ferrosoferric oxide

Lynparza is a trademark of the AstraZeneca group of companies.
©AstraZeneca 2017

Distributed by:
AstraZeneca Pharmaceuticals LP
Wilmington, DE 19850
For more information, call 1-800-236-9933 or go to www.Lynparza.com.

This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 8/2017

Reference ID: 4140741
Officer/Employee List
Application: NDA 206162/S-007
Lynparza® (Olaparib), Oral Capsules

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Balasubramaniam, Sanjeeve
Beaver, Julia A.
Griffiths, LaShawn
Ison, Gwynn
Mills, Sharon
Pierce, William
Venugopal, Rajesh
Wright, Kevin
APPLICATION NUMBER:

206162Orig1s007

MEDICAL REVIEW(S)
Division of Oncology Products 1

CLINICAL TEAM LEADER LABELING REVIEW

Application: NDA 206162/S-007
Name of Drug: LYNPARZA™ (olaparib) Capsules, 50 mg
Applicant: AstraZeneca, LP

Labeling Reviewed

Submission Date: May 17, 2017
Receipt Date: May 17, 2017

Background and Summary Description:

NDA 206162, olaparib capsules, is currently under accelerated approval. Supplement 007 was submitted by AstraZeneca on May 17, 2017 to add Section 6.2 to the USPI to add the post-marketing signal of “hypersensitivity characterized by rash and dermatitis” based on new data. After review of the justification for this addition, it was determined by the review team that it is reasonable to add this proposed language to Section 6.2 of the olaparib USPI.

NDA 208558, the tablet formulation of olaparib, which has a different bioavailability profile and is therefore non-interchangeable with the capsule formulation under accelerated approval, is due for a regular approval action by the PDUFA goal date of August 22, 2017. Because both the tablet and the capsule formulations will be on the market under the same proprietary name simultaneously, the applicant and Agency, including DMEPA, discussed specific strategies to minimize the potential for medication errors.

One action FDA has decided to take to aid in this risk mitigation is to update olaparib capsule labeling for NDA 206162 to add text regarding the lack of interchangeability of the two products in the Highlights, Section 2, and Medication Guide.

The Highlights section will read, “To avoid substitution errors and overdose, do not substitute Lynparza capsules with Lynparza tablets on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.”

Section 2.2 will read, “Lynparza is also available as 100 mg and 150 mg tablets. DO NOT substitute Lynparza capsules (50 mg) with Lynparza tablets (100 mg and 150 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation Refer to the full prescribing information for Lynparza tablets for specific tablet dosing.”

The Medication Guide will read, “Lynparza comes as capsules and tablets. Lynparza capsules and tablets are not the same. If your healthcare provider prescribes Lynparza capsules for you do not take Lynparza tablets. If you have any questions about Lynparza, talk with your healthcare provider or pharmacist.”

Reference ID: 4138504
The approval of NDA 208558 for the tablet formulation of olaparib will also change the accelerated approval of NDA 206162 for the fourth-and-beyond line of treatment of women with germline BRCA mutation-associated ovarian cancer to regular approval.

In order to fulfill the accelerated approval PMRs for NDA 206162, reference must be made to the clinical trial submitted to NDA 208558. This cross-reference will allow the warnings regarding non-interchangeability to be added to NDA 206162/S-007, and allow the removal of the accelerated approval language from the Highlights and Section 1 of the USPI for olaparib capsules.

The Agency has asked AstraZeneca to submit to NDA 206162/S-007 a letter of cross reference to the tablet NDA (208558). This will allow the cross-referencing of the Clinical Study Report for SOLO2, submitted to NDA 208558, to fulfill PMR 2824-1 of NDA 206162. Supplement 007, originally submitted as a labeling supplement, will be converted to an SE-7 efficacy supplement, as clinical data are needed to support the non-interchangeability language between capsule and tablet formulations and the change to regular approval for the fourth-line indication. In addition, the second Subpart H PMR from NDA 206162 (PMR 2824-2) will be released and reissued as a PMC for NDA 208558.

**Recommendation**

Approval of NDA 206162/S-007 is recommended. A letter of cross-reference should be issued by AstraZeneca to fulfill PMR 2824-1. PMR 2824-2 will be released from NDA 206162 and reissued as a PMC in the approval letter for NDA 208558. Labeling should be modified as described above.

Gwynn Ison, MD  
Medical Officer, DOP1

Sanjeeve Balasubramaniam, MD, MPH  
Clinical Team Leader (Acting), DOP1
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

GWYNN ISON  
08/11/2017

SANJEEVE BALASUBRAMANIAM  
08/11/2017
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

206162Orig1s007

OTHER REVIEW(S)
PATIENT LABELING REVIEW

Date: August 1, 2017

To: Julia Beaver, MD
Acting Director
Division of Oncology Products 1 (DOP1)

Through: LaShawn Griffiths, MSHS-PH, BSN, RN
Associate Director for Patient Labeling
Division of Medical Policy Programs (DMPP)

From: Sharon R. Mills, BSN, RN, CCRP
Senior Patient Labeling Reviewer
Division of Medical Policy Programs (DMPP)

Kevin Wright, PharmD
Regulatory Review Officer
Office of Prescription Drug Promotion (OPDP)

Subject: Review of Patient Labeling: Medication Guide (MG)

Drug Name (established name): LYNPARZA (olaparib)

Dosage Form and Route: capsules, for oral use

Application Type/Number: NDA 206162

Supplement Number: S-007 and S-008

Applicant: AstraZeneca Pharmaceuticals, LP
1 INTRODUCTION

On May 17, 2017, AstraZeneca Pharmaceuticals LP submitted for the Agency’s review a Prior Approval Supplement (PAS) - Labeling to their approved New Drug Application (NDA) 206162/S-007 for LYNPARZA (olaparib) capsules. The purpose of this supplement is to update the approved product labeling with updated information on the post-marketing signal of hypersensitivity characterized by rash and dermatitis based on new data.

On June 8, 2017, AstraZeneca Pharmaceuticals LP submitted for the Agency’s review a PAS - Labeling to their approved NDA 206162/S-008 for LYNPARZA (olaparib) capsules. The purpose of this supplement is to update the approved product labeling with updated information on the relative bioavailability of the capsule and tablet formulations of olaparib.

LYNPARZA (olaparib) tablets was originally approved on December 9, 2014, and is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

This collaborative review is written by the Division of Medical Policy Programs (DMPP) and the Office of Prescription Drug Promotion (OPDP) in response to a request by the Division of Oncology Products 1 (DOP1) on July 25, 2017, for DMPP and OPDP to review the Applicant’s proposed Medication Guide (MG) for LYNPARZ (olaparib) capsules.

2 MATERIAL REVIEWED

- Draft LYNPARZA (olaparib) capsules MG received on June 27, 2017, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on July 25, 2017.

- Draft LYNPARZA (olaparib) capsules Prescribing Information (PI) received on June 27, 2017, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on July 25, 2017.


3 REVIEW METHODS

In our collaborative review of the MG we:

- simplified wording and clarified concepts where possible
- ensured that the MG is consistent with the Prescribing Information (PI)
- removed unnecessary or redundant information
- ensured that the MG is free of promotional language or suggested revisions to ensure that it is free of promotional language
- ensured that the MG meets the Regulations as specified in 21 CFR 208.20
• ensured that the MG meets the criteria as specified in FDA’s Guidance for Useful Written Consumer Medication Information (published July 2006)

4 CONCLUSIONS

The MG is acceptable with our recommended changes.

5 RECOMMENDATIONS

• Please send these comments to the Applicant and copy DMPP and OPDP on the correspondence.

• Our collaborative review of the MG is appended to this memorandum. Consult DMPP and OPDP regarding any additional revisions made to the PI to determine if corresponding revisions need to be made to the MG.

Please let us know if you have any questions.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SHARON R MILLS
08/01/2017

KEVIN WRIGHT
08/02/2017

LASHAWN M GRIFFITHS
08/02/2017

Reference ID: 4133219
Memorandum

Date: July 31, 2017

To: Rajesh Venugopal, MPH, MBA
   Senior Regulatory Project Manager
   Division of Oncology Products 1
   Office of Hematology and Oncology Products

From: Kevin Wright, PharmD
       Regulatory Review Officer
       Office of Prescription Drug Promotion (OPDP)

Subject: Lynparza® (olaparib) capsules, for oral use
         NDA 206162 Supplement 007 and 008
         Office of Prescription Drug Promotion comments on proposed
         prescribing information (PI)

Office of Prescription Drug Promotion (OPDP) has reviewed the draft prescribing
information (PI) for Lynparza® (olaparib) capsules, for oral use as requested by
DOP1 in the consult dated July 25, 2017.

Supplement 007 is a prior approval supplement that proposes inclusion of
hypersensitivity reactions into the Postmarketing Experience section of the PI.

Supplement 008 is a prior approval supplement that proposes inclusion of
bioavailability data between the tablet and capsule formulation of Lynparza.

OPDP’s review of the proposed PI is based on the draft PI titled,
“SLR_007_008_NDA 206162_Combined annotated-draft-label_Submitted
6.22.17.doc” sent by electronic mail on July 25, 2017, to OPDP (Kevin Wright)
from DOP1 (Rajesh Venugopal). OPDP has no comments on the proposed PI.

The combined OPDP and Division of Medical Policy Programs (DMPP) review of
the patient package insert (PPI) will be provided under a separate cover.

If you have any questions, please feel free to contact, Kevin Wright at
(301) 796-3621 or kevin.wright@fda.hhs.gov. OPDP appreciates the opportunity
to provide comments on these materials. Thank you!
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KEVIN WRIGHT
07/31/2017